DSX Therapeutics, Inc. -Going After $19 Billion Sepsis Market

North Las Vegas-Based DSX Therapeutics has developed the first new diagnostic test to identify Sepsis 24 to 48 hours before the symptoms become apparent. In addition, DSX Therapeutics has also discovered a breakthrough therapy to treat this life-threatening problem.

Over 7 million people annually become susceptible to Sepsis and 250,000 Americans die from Sepsis each year. DSX Therapeutics is going after the $864 million diagnostic market and later the $19 billion treatment market for Sepsis. The scientists at DSX Therapeutics Inc. were conducting clinical trials for a new sepsis in vitro diagnostic (IVD) test, when they discovered that iNOS was an early biochemical marker for the onset of sepsis. They also realized that iNOS appeared to be centrally involved in the pathology of sepsis. The initial discovery culminated in the filing of patent applications to protect three novel therapeutic treatment modalities for sepsis and severe sepsis.